CD34 and acute myeloid leukemia: In AML CD34+ HSPC xenograft mice, inhibition of miR-181 increased differentiation of myeloid progenitors, reduced engraftment and infiltration of leukemic HSPCs into bone marrow and spleen, and ameliorated symptoms of leukemia.